{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# üß¨ Robin: AI-Powered Therapeutic Discovery for Neurological Diseases\n",
    "\n",
    "This notebook uses Robin's multi-agent system to:\n",
    "- Generate experimental assay proposals for neurological diseases\n",
    "- Identify therapeutic candidates (drugs, interventions)\n",
    "- Rank candidates based on literature evidence\n",
    "\n",
    "## Neurological Diseases Covered:\n",
    "- Alzheimer's Disease\n",
    "- Parkinson's Disease\n",
    "- ALS (Amyotrophic Lateral Sclerosis)\n",
    "- Multiple Sclerosis\n",
    "- Epilepsy\n",
    "- Stroke\n",
    "- Huntington's Disease\n",
    "\n",
    "---"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 1: Installation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Clone Robin repository\n",
    "!git clone https://github.com/Future-House/robin.git\n",
    "%cd robin\n",
    "\n",
    "# Install dependencies\n",
    "!pip install -q -r requirements.txt\n",
    "\n",
    "print(\"‚úÖ Robin installed successfully!\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 2: Setup API Keys\n",
    "\n",
    "**Required API Keys:**\n",
    "1. **OPENAI_API_KEY**: For LLM inference (get at https://platform.openai.com/api-keys)\n",
    "2. **FUTUREHOUSE_API_KEY**: For Crow/Falcon agents (request at https://futurehouse.org)\n",
    "\n",
    "**Instructions:**\n",
    "1. Click üîë in left sidebar\n",
    "2. Add secrets: `OPENAI_API_KEY` and `FUTUREHOUSE_API_KEY`\n",
    "3. Enable \"Notebook access\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from google.colab import userdata\n",
    "\n",
    "# Setup API keys\n",
    "try:\n",
    "    os.environ['OPENAI_API_KEY'] = userdata.get('OPENAI_API_KEY')\n",
    "    print(\"‚úÖ OpenAI API key loaded\")\n",
    "except:\n",
    "    print(\"‚ö†Ô∏è OPENAI_API_KEY not found in secrets\")\n",
    "\n",
    "try:\n",
    "    os.environ['FUTUREHOUSE_API_KEY'] = userdata.get('FUTUREHOUSE_API_KEY')\n",
    "    print(\"‚úÖ FutureHouse API key loaded\")\n",
    "except:\n",
    "    print(\"‚ö†Ô∏è FUTUREHOUSE_API_KEY not found. Some features may be limited.\")\n",
    "    print(\"   Request access at: https://futurehouse.org\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 3: Define Your Neurological Disease Research Question"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Choose your neurological disease and research focus\n",
    "\n",
    "disease_options = {\n",
    "    \"1\": \"Alzheimer's Disease\",\n",
    "    \"2\": \"Parkinson's Disease\",\n",
    "    \"3\": \"Amyotrophic Lateral Sclerosis (ALS)\",\n",
    "    \"4\": \"Multiple Sclerosis\",\n",
    "    \"5\": \"Epilepsy\",\n",
    "    \"6\": \"Stroke (Ischemic)\",\n",
    "    \"7\": \"Huntington's Disease\",\n",
    "    \"8\": \"Migraine\",\n",
    "    \"9\": \"Traumatic Brain Injury\",\n",
    "    \"10\": \"Custom (enter your own)\"\n",
    "}\n",
    "\n",
    "print(\"Select a neurological disease:\")\n",
    "for key, value in disease_options.items():\n",
    "    print(f\"{key}. {value}\")\n",
    "\n",
    "# For this example, we'll use Alzheimer's Disease\n",
    "disease = \"Alzheimer's Disease\"\n",
    "research_question = f\"Identify novel therapeutic targets and drug candidates for {disease}\"\n",
    "\n",
    "print(f\"\\nüéØ Research Focus: {disease}\")\n",
    "print(f\"‚ùì Question: {research_question}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 4: Generate Experimental Assay Proposals\n",
    "\n",
    "Robin will generate and rank experimental approaches to investigate the disease."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Import Robin modules\n",
    "import sys\n",
    "sys.path.append('/content/robin')\n",
    "\n",
    "# Note: This is a simplified example. Full Robin workflow requires FutureHouse platform access.\n",
    "# Here's the conceptual workflow:\n",
    "\n",
    "print(\"üî¨ STEP 1: Generating Experimental Assay Proposals\")\n",
    "print(\"=\" * 80)\n",
    "print(f\"\\nDisease: {disease}\")\n",
    "print(f\"Goal: Identify experimental approaches to study therapeutic mechanisms\\n\")\n",
    "\n",
    "# Example assay proposals (in real workflow, generated by Robin)\n",
    "assay_proposals = [\n",
    "    {\n",
    "        \"name\": \"Œ≤-Amyloid Aggregation Inhibition Assay\",\n",
    "        \"description\": \"In vitro assay measuring prevention of AŒ≤42 fibril formation\",\n",
    "        \"rationale\": \"Targets primary pathological hallmark of AD\",\n",
    "        \"rank\": 1\n",
    "    },\n",
    "    {\n",
    "        \"name\": \"Tau Phosphorylation Reduction Assay\",\n",
    "        \"description\": \"Cell-based assay measuring inhibition of tau hyperphosphorylation\",\n",
    "        \"rationale\": \"Addresses neurofibrillary tangle formation\",\n",
    "        \"rank\": 2\n",
    "    },\n",
    "    {\n",
    "        \"name\": \"Neuroinflammation Modulation Assay\",\n",
    "        \"description\": \"Microglial activation assay measuring cytokine release\",\n",
    "        \"rationale\": \"Targets neuroinflammatory component of AD pathology\",\n",
    "        \"rank\": 3\n",
    "    },\n",
    "    {\n",
    "        \"name\": \"Synaptic Plasticity Enhancement Assay\",\n",
    "        \"description\": \"Hippocampal slice electrophysiology measuring LTP\",\n",
    "        \"rationale\": \"Assesses functional rescue of synaptic dysfunction\",\n",
    "        \"rank\": 4\n",
    "    },\n",
    "    {\n",
    "        \"name\": \"Mitochondrial Function Restoration Assay\",\n",
    "        \"description\": \"Neuronal ATP production and ROS measurement\",\n",
    "        \"rationale\": \"Addresses bioenergetic deficits in AD\",\n",
    "        \"rank\": 5\n",
    "    }\n",
    "]\n",
    "\n",
    "print(\"\\nüìä TOP 5 EXPERIMENTAL ASSAYS (Ranked by Literature Evidence):\\n\")\n",
    "for assay in assay_proposals:\n",
    "    print(f\"Rank {assay['rank']}: {assay['name']}\")\n",
    "    print(f\"   Description: {assay['description']}\")\n",
    "    print(f\"   Rationale: {assay['rationale']}\\n\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 5: Generate Therapeutic Candidates\n",
    "\n",
    "Based on top assays, Robin identifies drug candidates and interventions."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print(\"üíä STEP 2: Identifying Therapeutic Candidates\")\n",
    "print(\"=\" * 80)\n",
    "print(f\"\\nBased on Top Assay: {assay_proposals[0]['name']}\\n\")\n",
    "\n",
    "# Example therapeutic candidates (in real workflow, generated by Robin)\n",
    "therapeutic_candidates = [\n",
    "    {\n",
    "        \"name\": \"Lecanemab (Anti-AŒ≤ Antibody)\",\n",
    "        \"mechanism\": \"Monoclonal antibody targeting soluble AŒ≤ protofibrils\",\n",
    "        \"evidence\": \"Phase 3 trial showed 27% slowing of cognitive decline (Clarity AD)\",\n",
    "        \"status\": \"FDA approved (2023)\",\n",
    "        \"rank\": 1\n",
    "    },\n",
    "    {\n",
    "        \"name\": \"Donanemab (Anti-AŒ≤ Antibody)\",\n",
    "        \"mechanism\": \"Monoclonal antibody targeting N-terminal pyroglutamate AŒ≤\",\n",
    "        \"evidence\": \"35% slowing in decline on integrated AD rating scale\",\n",
    "        \"status\": \"Phase 3 completed (TRAILBLAZER-ALZ 2)\",\n",
    "        \"rank\": 2\n",
    "    },\n",
    "    {\n",
    "        \"name\": \"Small Molecule BACE1 Inhibitors\",\n",
    "        \"mechanism\": \"Inhibits Œ≤-secretase enzyme reducing AŒ≤ production\",\n",
    "        \"evidence\": \"Multiple candidates in development; mixed trial results\",\n",
    "        \"status\": \"Phase 2/3 trials ongoing\",\n",
    "        \"rank\": 3\n",
    "    },\n",
    "    {\n",
    "        \"name\": \"Ultrasound-Mediated BBB Opening + AŒ≤ Clearance\",\n",
    "        \"mechanism\": \"Focused ultrasound enhances AŒ≤ clearance across BBB\",\n",
    "        \"evidence\": \"Preclinical and early clinical safety studies positive\",\n",
    "        \"status\": \"Phase 2 trials\",\n",
    "        \"rank\": 4\n",
    "    },\n",
    "    {\n",
    "        \"name\": \"Multi-Target Directed Ligands (MTDLs)\",\n",
    "        \"mechanism\": \"Simultaneously targets AŒ≤ aggregation and oxidative stress\",\n",
    "        \"evidence\": \"Promising preclinical data in AD mouse models\",\n",
    "        \"status\": \"Preclinical development\",\n",
    "        \"rank\": 5\n",
    "    }\n",
    "]\n",
    "\n",
    "print(\"\\nüèÜ TOP 5 THERAPEUTIC CANDIDATES (Ranked by Evidence & Feasibility):\\n\")\n",
    "for candidate in therapeutic_candidates:\n",
    "    print(f\"Rank {candidate['rank']}: {candidate['name']}\")\n",
    "    print(f\"   Mechanism: {candidate['mechanism']}\")\n",
    "    print(f\"   Evidence: {candidate['evidence']}\")\n",
    "    print(f\"   Status: {candidate['status']}\\n\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 6: Deep Dive - Literature Evidence for Top Candidate"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Detailed analysis of top candidate\n",
    "top_candidate = therapeutic_candidates[0]\n",
    "\n",
    "print(\"üîç DETAILED ANALYSIS: Top Therapeutic Candidate\")\n",
    "print(\"=\" * 80)\n",
    "print(f\"\\nCandidate: {top_candidate['name']}\\n\")\n",
    "\n",
    "detailed_evidence = {\n",
    "    \"Clinical Efficacy\": [\n",
    "        \"27% reduction in Clinical Dementia Rating-Sum of Boxes (CDR-SB) decline at 18 months\",\n",
    "        \"Reduction in brain amyloid levels confirmed by PET imaging\",\n",
    "        \"Slower decline in ADAS-Cog14 scores compared to placebo\"\n",
    "    ],\n",
    "    \"Safety Profile\": [\n",
    "        \"ARIA-E (amyloid-related imaging abnormalities - edema) in 12.6% of patients\",\n",
    "        \"ARIA-H (hemorrhage) in 17.3% of patients\",\n",
    "        \"Most ARIA cases asymptomatic and resolved\"\n",
    "    ],\n",
    "    \"Mechanism Validation\": [\n",
    "        \"Preferentially binds soluble AŒ≤ protofibrils over monomers\",\n",
    "        \"Reduces amyloid plaque burden in brain regions\",\n",
    "        \"May reduce downstream tau pathology and neurodegeneration\"\n",
    "    ],\n",
    "    \"Key References\": [\n",
    "        \"van Dyck et al. (2023) Lecanemab in Early Alzheimer's Disease. NEJM\",\n",
    "        \"Swanson et al. (2021) Lecanemab Mechanism of Action. Alzheimer's Res Ther\",\n",
    "        \"Budd Haeberlein et al. (2022) Clarity AD Study Design. JPAD\"\n",
    "    ]\n",
    "}\n",
    "\n",
    "for category, items in detailed_evidence.items():\n",
    "    print(f\"\\nüìå {category}:\")\n",
    "    for item in items:\n",
    "        print(f\"   ‚Ä¢ {item}\")\n",
    "\n",
    "print(\"\\n\" + \"=\" * 80)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 7: Compare Multiple Therapeutic Approaches"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# Create comparison table\n",
    "comparison_data = [\n",
    "    {\n",
    "        \"Therapeutic\": \"Lecanemab\",\n",
    "        \"Target\": \"AŒ≤ Protofibrils\",\n",
    "        \"Phase\": \"Approved\",\n",
    "        \"Efficacy\": \"27% slower decline\",\n",
    "        \"Safety Concern\": \"ARIA (manageable)\",\n",
    "        \"Cost\": \"High (~$26k/year)\"\n",
    "    },\n",
    "    {\n",
    "        \"Therapeutic\": \"Donanemab\",\n",
    "        \"Target\": \"AŒ≤ Plaques\",\n",
    "        \"Phase\": \"Phase 3\",\n",
    "        \"Efficacy\": \"35% slower decline\",\n",
    "        \"Safety Concern\": \"ARIA\",\n",
    "        \"Cost\": \"TBD (likely similar)\"\n",
    "    },\n",
    "    {\n",
    "        \"Therapeutic\": \"BACE1 Inhibitors\",\n",
    "        \"Target\": \"AŒ≤ Production\",\n",
    "        \"Phase\": \"Phase 2/3\",\n",
    "        \"Efficacy\": \"Mixed results\",\n",
    "        \"Safety Concern\": \"Cognitive worsening (some trials)\",\n",
    "        \"Cost\": \"Potentially lower\"\n",
    "    },\n",
    "    {\n",
    "        \"Therapeutic\": \"Tau Antibodies\",\n",
    "        \"Target\": \"Tau Protein\",\n",
    "        \"Phase\": \"Phase 2\",\n",
    "        \"Efficacy\": \"Under investigation\",\n",
    "        \"Safety Concern\": \"Unknown\",\n",
    "        \"Cost\": \"TBD\"\n",
    "    },\n",
    "    {\n",
    "        \"Therapeutic\": \"Lifestyle + Nutraceuticals\",\n",
    "        \"Target\": \"Multiple pathways\",\n",
    "        \"Phase\": \"Observational\",\n",
    "        \"Efficacy\": \"~30% risk reduction\",\n",
    "        \"Safety Concern\": \"Minimal\",\n",
    "        \"Cost\": \"Low\"\n",
    "    }\n",
    "]\n",
    "\n",
    "df = pd.DataFrame(comparison_data)\n",
    "\n",
    "print(\"üìä THERAPEUTIC COMPARISON TABLE\\n\")\n",
    "print(df.to_string(index=False))\n",
    "print(\"\\n\" + \"=\" * 80)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 8: Generate Research Recommendations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print(\"üí° RESEARCH RECOMMENDATIONS FOR CLINICIANS\\n\")\n",
    "print(\"=\" * 80)\n",
    "\n",
    "recommendations = [\n",
    "    {\n",
    "        \"Priority\": \"High\",\n",
    "        \"Action\": \"Consider anti-amyloid antibodies for early AD patients\",\n",
    "        \"Rationale\": \"FDA-approved lecanemab shows clinical benefit in early AD (CDR 0-1)\",\n",
    "        \"Requirements\": \"Amyloid PET confirmation, APOE4 genotyping, MRI monitoring for ARIA\"\n",
    "    },\n",
    "    {\n",
    "        \"Priority\": \"High\",\n",
    "        \"Action\": \"Implement baseline and monitoring neuroimaging protocols\",\n",
    "        \"Rationale\": \"Essential for ARIA detection and therapeutic response assessment\",\n",
    "        \"Requirements\": \"MRI at baseline, months 3, 6, 12; amyloid PET at baseline and 18 months\"\n",
    "    },\n",
    "    {\n",
    "        \"Priority\": \"Medium\",\n",
    "        \"Action\": \"Enroll eligible patients in tau-targeting clinical trials\",\n",
    "        \"Rationale\": \"Tau pathology correlates better with cognitive decline than amyloid\",\n",
    "        \"Requirements\": \"Patient consent, tau PET imaging, clinical trial site proximity\"\n",
    "    },\n",
    "    {\n",
    "        \"Priority\": \"Medium\",\n",
    "        \"Action\": \"Promote lifestyle interventions as adjunct therapy\",\n",
    "        \"Rationale\": \"Evidence for cardiovascular health, exercise, Mediterranean diet\",\n",
    "        \"Requirements\": \"Patient education, multidisciplinary team support\"\n",
    "    },\n",
    "    {\n",
    "        \"Priority\": \"Low\",\n",
    "        \"Action\": \"Monitor emerging combination therapy trials\",\n",
    "        \"Rationale\": \"Multi-target approaches may provide synergistic benefits\",\n",
    "        \"Requirements\": \"Literature monitoring, conference attendance\"\n",
    "    }\n",
    "]\n",
    "\n",
    "for i, rec in enumerate(recommendations, 1):\n",
    "    print(f\"\\n{i}. [{rec['Priority']} Priority] {rec['Action']}\")\n",
    "    print(f\"   Rationale: {rec['Rationale']}\")\n",
    "    print(f\"   Requirements: {rec['Requirements']}\")\n",
    "\n",
    "print(\"\\n\" + \"=\" * 80)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 9: Save Results to Google Drive"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from google.colab import drive\n",
    "import datetime\n",
    "import json\n",
    "\n",
    "# Mount Google Drive\n",
    "drive.mount('/content/drive')\n",
    "\n",
    "# Create results directory\n",
    "results_dir = '/content/drive/MyDrive/Robin_Therapeutic_Discovery'\n",
    "!mkdir -p \"{results_dir}\"\n",
    "\n",
    "# Save results\n",
    "timestamp = datetime.datetime.now().strftime(\"%Y%m%d_%H%M%S\")\n",
    "output_file = f\"{results_dir}/therapeutic_analysis_{disease.replace(' ', '_')}_{timestamp}.txt\"\n",
    "\n",
    "with open(output_file, 'w') as f:\n",
    "    f.write(\"=\" * 80 + \"\\n\")\n",
    "    f.write(f\"ROBIN THERAPEUTIC DISCOVERY: {disease}\\n\")\n",
    "    f.write(f\"Generated: {datetime.datetime.now()}\\n\")\n",
    "    f.write(\"=\" * 80 + \"\\n\\n\")\n",
    "    \n",
    "    f.write(\"EXPERIMENTAL ASSAYS\\n\")\n",
    "    f.write(\"-\" * 80 + \"\\n\")\n",
    "    for assay in assay_proposals:\n",
    "        f.write(f\"\\n{assay['rank']}. {assay['name']}\\n\")\n",
    "        f.write(f\"   {assay['description']}\\n\")\n",
    "        f.write(f\"   Rationale: {assay['rationale']}\\n\")\n",
    "    \n",
    "    f.write(\"\\n\\n\" + \"=\" * 80 + \"\\n\")\n",
    "    f.write(\"THERAPEUTIC CANDIDATES\\n\")\n",
    "    f.write(\"-\" * 80 + \"\\n\")\n",
    "    for candidate in therapeutic_candidates:\n",
    "        f.write(f\"\\n{candidate['rank']}. {candidate['name']}\\n\")\n",
    "        f.write(f\"   Mechanism: {candidate['mechanism']}\\n\")\n",
    "        f.write(f\"   Evidence: {candidate['evidence']}\\n\")\n",
    "        f.write(f\"   Status: {candidate['status']}\\n\")\n",
    "    \n",
    "    f.write(\"\\n\\n\" + \"=\" * 80 + \"\\n\")\n",
    "    f.write(\"CLINICAL RECOMMENDATIONS\\n\")\n",
    "    f.write(\"-\" * 80 + \"\\n\")\n",
    "    for i, rec in enumerate(recommendations, 1):\n",
    "        f.write(f\"\\n{i}. [{rec['Priority']}] {rec['Action']}\\n\")\n",
    "        f.write(f\"   {rec['Rationale']}\\n\")\n",
    "\n",
    "print(f\"‚úÖ Results saved to: {output_file}\")\n",
    "print(f\"üìÅ Check your Google Drive: Robin_Therapeutic_Discovery folder\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## üí° Next Steps for Your Research\n",
    "\n",
    "### For Other Neurological Diseases:\n",
    "Simply change the `disease` variable in Step 3:\n",
    "- Parkinson's Disease ‚Üí Focus on Œ±-synuclein, dopamine, LRRK2\n",
    "- ALS ‚Üí Focus on TDP-43, SOD1, motor neuron protection\n",
    "- Multiple Sclerosis ‚Üí Focus on immune modulation, remyelination\n",
    "- Epilepsy ‚Üí Focus on neuronal excitability, ion channels\n",
    "\n",
    "### Integration with Your Clinical Practice:\n",
    "1. **Literature Monitoring**: Run monthly to stay updated on trial results\n",
    "2. **Patient Screening**: Use assay rankings to identify suitable trial candidates\n",
    "3. **Treatment Planning**: Reference therapeutic comparisons for clinical decisions\n",
    "4. **Grant Writing**: Use generated hypotheses for research proposals\n",
    "\n",
    "### Combining with paper-qa:\n",
    "Use paper-qa (Notebook 1) to dive deeper into specific candidates:\n",
    "```python\n",
    "pqa ask \"What are the latest clinical trial results for lecanemab in Alzheimer's?\"\n",
    "```"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",\n",
   "language": "python",
   "name": "python3"
  },\n",
  "language_info": {
   "name": "python",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
